Castle Biosciences Reports First Quarter 2026 Results
Castle Biosciences reported Q1 2026 revenue of $83.7 million, down from $88.0 million in the prior year due to known headwinds including a Medicare coverage change and IDgenetix discontinuation. Despite the revenue decline, core test reports (DecisionDx-Melanoma and TissueCypher) grew 36% year-over-year, with TissueCypher volumes surging 58% to 11,745 tests. Based on Q1 performance and business confidence, management raised full-year 2026 revenue guidance to $345-355 million from $340-350 million.
Key figures
- Revenue
- 83700000
- Guidance
- FY26 revenue $345-355 million, raised from $340-350 million
- Gross margin
- 73%
- Cash position
- 261700000
- Adjusted gross margin
- 76%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.